Rare Disease Development Built Around Biotech Companies
Rare disease development combines scientific complexity, dispersed patient populations and evolving regulatory pathways, requiring integrated expertise across clinical, regulatory and operational disciplines. Patient-centerd science, orphan drug strategy and multidisciplinary collaboration are central to successful program progression.
Evestia Clinical provides integrated scientific partnership and senior program leadership across Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics and Clinical Data Management, through our Full-Service CRO model or embedded specialists via FSP Solutions.
Experienced Rare Disease Medical Specialists
Direct access to scientists and clinicians with hands-on expertise across rare and ultra-rare disease development, providing strategic guidance rather than operational processing.
Senior Program Leadership
Senior-led delivery means faster decisions, clearer communication and greater operational responsiveness throughout program execution.
Integrated Scientific Expertise
Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics, Medical Writing and Pharmacokinetics working as one coordinated team across every rare disease program.
Flexible Delivery Models
Full-Service CRO and FSP Solutions that scale with program evolution and scientific requirements, providing integrated capability at every stage of development.
Rare Disease Expertise at a Glance
The depth behind these figures shapes every program decision, from patient recruitment strategy and advocacy engagement to regulatory submissions and biostatistical planning in small populations.
120+
Rare Disease Studies Supported
Across multiple indications and patient populations
50%
Team with Direct Rare Disease Expertise
Specialist rare disease experience
Adult & Pediatric
Rare Disease Development Experience
Supporting diverse patient populations
Patient-Centric
Clinical Trial Approach
Patient outcomes at the center of every program
Foundations of Successful Rare Disease Development
Successful rare disease programs are built on adaptive statistical methodologies, specialist investigator networks, patient advocacy engagement and integrated regulatory planning. Patient advocacy organizations hold concentrated knowledge of the patient community: where patients are, what barriers they face and what outcomes matter most. Early, structured engagement strengthens study design, endpoint selection and program planning throughout development.
Small population statistics require innovative, adaptive methodologies tailored to each indication. Specialist investigator networks and integrated Regulatory Affairs support help sponsors build programs designed for success across Phase I, Phase II and Phase III development. Common program considerations include:
Bringing Therapies to Rare Disease Patients Requires More Than Operational Delivery
Rare disease development combines patient-centerd science, specialist investigator engagement, adaptive methodologies and integrated regulatory planning to support successful program progression. Limited patient populations, novel endpoints and evolving regulatory frameworks each require thoughtful scientific design from the earliest stages of development.
The patient voice influences protocol design, endpoint selection and regulatory confidence. Specialist investigators, caregivers and advocacy organizations contribute meaningfully when engaged early. Working in alignment with Clinical Trial Management, Medical Affairs, Regulatory Affairs and Clinical Data Management, Evestia Clinical integrates scientific depth with patient-centerd delivery throughout.
Rare Disease Clinical Trial Services
Integrated scientific collaboration, multidisciplinary delivery and consistent program leadership support scientific quality and regulatory confidence at every stage. Every service below is delivered within one coordinated team, with each function aligned towards the same program outcome.
Clinical Trial Management
Providing program leadership and oversight throughout complex rare disease studies from initiation through close-out.
Learn moreClinical Operations
Integrated clinical operations support across rare disease programs, coordinating investigators, sites, vendors and study activities throughout the lifecycle.
Learn moreClinical Monitoring
Supporting investigator sites while maintaining patient safety, protocol compliance and data quality across geographically dispersed rare disease sites.
Learn moreClinical Site Management
Working closely with specialist centers and investigators to optimize recruitment, site performance and patient engagement throughout the study.
Learn moreStudy Start-Up Services
Accelerating site feasibility, selection and activation strategies to reduce timelines from protocol development to first patient enrolled.
Learn moreRegulatory Affairs
Supporting orphan drug strategies, regulatory submissions, accelerated pathway applications and global development interactions with FDA, EMA and MHRA.
Learn moreClinical Data Management
Managing complex datasets while maintaining data quality, regulatory readiness and CDISC-compliant outputs for rare disease submissions.
Learn moreBiostatistics
Providing statistical methodologies tailored to small patient populations, novel endpoints and rare disease study designs.
Learn moreMedical Affairs
Physician-led medical monitoring, medical strategy and safety review providing therapeutic expertise throughout rare disease development.
Learn morePharmacovigilance
Delivering comprehensive safety oversight across development and post-marketing activities for rare disease programs.
Learn moreMedical Writing
Preparing protocols, investigator brochures, orphan drug applications and regulatory documentation for rare disease submissions.
Learn morePharmacokinetics
Supporting PK modeling, small-population analyzes and dose optimization strategies tailored to rare disease development programs.
Learn moreFSP Solutions
Dedicated embedded rare disease specialists available through our Functional Service Provider model for sponsors requiring flexible resource scaling.
Learn moreOrphan Drug Development Expertise
Early regulatory planning is one of the most valuable strategic decisions a rare disease sponsor can make. Orphan designation pathways across the FDA, EMA, MHRA and other jurisdictions offer market exclusivity, fee reductions and access to accelerated development routes, for programs that incorporate them from the outset.
Through our Orphan Drug Development expertise and Regulatory Affairs capabilities, Evestia Clinical helps sponsors:
- Evaluate orphan designation opportunities
- Develop regulatory strategies for FDA and EMA orphan pathways
- Prepare submission documentation for orphan designation applications
- Engage with regulatory authorities throughout the development lifecycle
- Maximize development incentives including market exclusivity
- Support accelerated pathway applications
- Plan pediatric rare disease development programs
Early regulatory planning can significantly improve program efficiency and long-term development success. Sponsors developing therapies for rare pediatric diseases may also benefit from FDA Rare Pediatric Disease Priority Review Vouchers, an additional incentive available for programs meeting specific criteria.
Supporting Rare Disease Programs from First-in-Human Studies to Regulatory Approval
Continuity across phases is critical in rare disease development. The decisions made in Phase I, from safety assessment design to biomarker strategy, shape feasibility at Phase III. Regulatory Affairs and Clinical Trial Management are aligned from the outset, with Orphan Drug Development expertise incorporated from Phase I through to Phase III registration.
Supporting Ultra-Rare Disease Development
When patient populations number in the hundreds globally, each development decision carries greater scientific significance. Generating credible, submission-ready evidence requires adaptive trial designs, natural history studies, real-world evidence, external control arms and tailored statistical approaches suited to small, heterogeneous cohorts.
Targeted recruitment strategies, patient advocacy engagement and flexible operational models ensure every patient interaction contributes meaningful scientific and regulatory value. Many ultra-rare programs benefit from advanced therapy approaches: our Cell and Gene Therapy CRO expertise supports sponsors developing these modalities, combined with Orphan Drug Development knowledge to maximize available regulatory incentives.
Rare Disease Development Across Every Phase
First-in-human and early safety studies in rare disease populations, with Phase I protocols designed around limited patient availability and the specific safety considerations of each indication.
Learn moreProof of concept, dose optimization and adaptive study designs that maximize meaningful efficacy data from limited patient populations.
Learn moreMultinational registration and pivotal programs, with coordinated site activation, dispersed patient access and consistent quality across specialist treatment centers globally.
Learn moreRare Disease Expertise Across Key Therapeutic Areas
Rare Oncology
Supporting sponsors developing therapies for rare and orphan cancer indications, combining oncology expertise with rare disease operational strategies.
Learn moreNeurology CRO
Extensive experience across neurological and neurodegenerative rare diseases including ALS, neuromuscular disorders and rare CNS conditions.
Learn moreCell & Gene Therapy CRO
Providing specialist support for advanced therapies targeting rare genetic disorders through our dedicated Cell & Gene Therapy expertise.
Learn morePediatric Rare Diseases
Supporting development programs involving children and young people through patient-centerd operational approaches and pediatric-focused study design.
Learn morePatient-Centric Rare Disease Development
Patient engagement is a scientific and regulatory discipline that shapes study design, endpoint selection and participant experience throughout development. Communities engaged from the earliest stages help sponsors select more relevant endpoints, build practical protocols and achieve stronger regulatory confidence. The FDA and EMA have increasingly emphasised patient-reported outcomes and community involvement in rare disease submissions.
Evestia Clinical works closely with:
- Patient advocacy groups
- Caregiver communities
- Specialist investigators
- Rare disease centers of excellence
This collaborative approach improves recruitment, strengthens retention, reduces patient burden and generates more meaningful clinical evidence for regulatory submissions and program decision-making.
Why Sponsors Choose Evestia Clinical for Rare Disease Clinical Trials
The rare disease CRO partner a sponsor chooses shapes every aspect of program delivery, from how efficiently specialist patients are recruited to how confidently leadership can navigate regulatory interactions. As a specialist Biotech CRO, Evestia Clinical is structured to give sponsors the scientific depth, operational agility and senior access that rare disease programs demand.
Rare Disease Knowledge Embedded in Every Program
Deep therapeutic knowledge across rare and ultra-rare disease development, built across more than 120 rare disease studies and 50% direct team expertise, provides the scientific foundation that complex programs depend on. Experienced scientific guidance embedded throughout program delivery.
Patient-Centred Development That Strengthens Regulatory Confidence
Patient advocacy engagement, caregiver community partnerships and participant-focused study design strengthen endpoint selection, recruitment and participant experience. The patient voice at the center of every program decision is both an ethical commitment and a regulatory advantage.
Global Patient Access Through Established Investigator Networks
Established rare disease site networks, advocacy partnerships and multinational study delivery expertise support access to dispersed patient populations. International programs are coordinated with consistent quality, regulatory alignment and a patient-centerd approach throughout.
Maximizing Orphan Drug Incentives and Regulatory Pathways
Expertise across FDA Orphan Drug Designation, EMA Orphan Designation, MHRA and Health Canada orphan frameworks, accelerated regulatory pathways and development incentive strategies supports sponsors in maximizing regulatory advantages and improving program efficiency from the outset.
A Scientific Partner Built for Biotechnology Companies
Senior-led program delivery, direct communication and integrated scientific collaboration give biotechnology organizations the responsiveness they need to support confident program progression and informed development decisions throughout the lifecycle.
Flexible Partnerships That Scale With Your Program
Rare disease programs supported through our Full-Service CRO model or via our FSP Solutions provide sponsors with the flexibility to scale scientific expertise as program requirements and organizational priorities evolve.
Embedded Specialists Aligned With Sponsor Requirements
Dedicated rare disease specialists available through our Functional Service Provider (FSP) Solutions model provide scalable embedded expertise aligned with sponsor requirements, for organizations seeking integrated rare disease capability within their own teams.
How Evestia Strengthens Rare Disease Development
Patient-centerd development, integrated scientific expertise and coordinated regulatory support give sponsors the program confidence and scientific foundation to advance rare disease programs from first-in-human studies through global registration.
Global Patient Recruitment
Geographically dispersed populations make recruitment a scientific and operational priority in rare disease development. Specialist site networks, global investigator relationships and patient registry partnerships help sponsors locate, engage and enroll eligible patients throughout the program.
Advocacy Group Engagement
Patient advocacy organizations hold concentrated knowledge of the patient community. Early engagement strengthens recruitment feasibility, protocol design and regulatory confidence, ensuring programs reflect what matters most to the communities they are designed to help.
Orphan Drug Strategy
A well-integrated orphan drug strategy helps sponsors maximize available regulatory incentives through early strategic planning. FDA Orphan Drug Designation, EMA Orphan Designation and Conditional Marketing Authorization can meaningfully accelerate timelines and improve program outcomes.
Ultra-Rare Diseases
When populations number in the hundreds globally, program design requires highly specialized planning and scientific collaboration. Adaptive study designs, global site coordination and close regulatory collaboration support credible evidence generation from very small patient cohorts.
Small Population Study Design
Small rare disease populations benefit from adaptive designs, natural history studies, external control arms and innovative statistical approaches tailored to each indication. These methodologies help sponsors generate submission-ready evidence from small, heterogeneous cohorts.
Scalable Rare Disease Expertise
As rare disease portfolios evolve, access to embedded scientific expertise and integrated partnership becomes a strategic priority. Full-Service CRO delivery and Functional Service Provider (FSP) specialists provide the depth and program flexibility needed at each stage of development.
Rare Disease CRO Support for Biotech Companies
Biotechnology companies advancing rare disease programs need scalable scientific expertise, patient-centerd development experience and the flexibility to access both throughout the program lifecycle. Evestia Clinical provides integrated scientific partnership supporting programs from Phase I through registration.
Strategic control stays with the sponsor; scientific depth and collaborative delivery come from Evestia. Available through our Full-Service CRO model or embedded FSP specialists, the partnership adapts as programs evolve. As a Biotech CRO with dedicated rare disease expertise, Evestia Clinical brings the scientific understanding and operational capability that biotechnology innovation in rare disease requires.
Frequently Asked Questions About Rare Disease CRO Services
Explore Related Clinical Development Services
Service Pages
Development Phases
Related Therapeutic Expertise
Helping Rare Disease Innovators Bring New Therapies to Patients
Patient-centerd development, integrated scientific expertise and collaborative partnership from first-in-human studies to global registration. Evestia Clinical is the rare disease partner built for biotechnology companies advancing programs where scientific rigor, patient focus and regulatory success matter equally.